4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease



Status:Completed
Conditions:Renal Impairment / Chronic Kidney Disease, Anemia
Therapuetic Areas:Hematology, Nephrology / Urology
Healthy:No
Age Range:18 - 99
Updated:11/16/2017
Start Date:May 23, 2012
End Date:May 27, 2013

Use our guide to learn which trials are right for you!

A Four-week, Phase IIa, Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Switching Subjects From a Stable Dose of Recombinant Human Erythropoietin to GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

This is a four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center
study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from stable
rhEPO to GSK1278863 in approximately 68 hemodialysis-dependent subjects with anemia
associated with chronic kidney disease. The study consists of a screening phase of 2 weeks, a
4-week treatment phase and a 2-week follow-up phase. The range of Hgb values for study
eligibility is 9.5-12.0 g/dL and the subjects must have received the same rhEPO product with
total weekly doses that varied by no more than 50% during the 4 weeks prior to the Screening
visit (Week -1. This study aims to estimate the relationship between dose of GSK1278863 and
Hgb response in hemodialysis-dependent (HDD) subjects with anemia associated with chronic
kidney disease after switching from a stable maintenance dose of recombinant human
erythropoetin (rhEPO).

This is a four-week, Phase IIa, randomized, active-controlled, parallel-group, multi-center
study to evaluate the safety, efficacy and pharmacokinetics of switching subjects from stable
rhEPO to GSK1278863 in approximately 68 hemodialysis-dependent subjects with anemia
associated with chronic kidney disease. The study consists of a screening phase of 2 weeks, a
4-week treatment phase and a 2-week follow-up phase. The range of Hgb values for study
eligibility is 9.5-12.0 g/dL and the subjects must have received the same rhEPO product with
total weekly doses that varied by no more than 50% during the 4 weeks prior to the Screening
visit (Week -1. Eligible subjects, stratified by their prior rhEPO dose will be randomized in
equal proportions to receive double-blind GSK1278863 0.5 mg, 2 mg or 5 mg QD (after
discontinuing their rhEPO), or to continue to receive their existing type and dose of rhEPO
(epoetins or their biosimilars, or darbepoetin). Study treatment will be stopped if Hgb
values fall outside of the protocol pre-specified ranges. Subject completion is defined as
completion of all study phases including the follow-up phase.

This study aims to estimate the relationship between dose of GSK1278863 and Hgb response in
hemodialysis-dependent (HDD) subjects with anemia associated with chronic kidney disease
after switching from a stable maintenance dose of recombinant human erythropoetin (rhEPO). In
addition, the study will characterize the effect of GSK1278863 on various pharmacokinetic
(PK)/pharmacodynamic (PD) markers, and will investigate the safety and tolerability of
GSK1278863.

An early interim analysis of the Hgb data is planned after approximately 20 subjects from
cohort 1 have completed 3 weeks of treatment. Depending upon the interim findings, a second
cohort of subjects may be added to investigate an additional GSK1278863 dose arm. Recruitment
to the first cohort will continue during the interim analysis.

A second interim analysis is planned after approximately 48 subjects from cohort 1 have
completed 4 weeks treatment. The purpose of this interim is three-fold, to investigate if a
second cohort of subjects may be added, to facilitate early development of dose-response and
PK/PD statistical models, and to generate interim results to facilitate design and dosing
decisions for the next trial.

Inclusion Criteria:

1. Age and weight: >/=18 years of age and >/=45 kg (weight post-dialysis).

2. On three times weekly hemodialysis for at least 8 weeks, irrespective of eGFR values
and stage of chronic kidney disease (CKD).

3. A single-pool Kt/Vurea of >/=1.2 based on a historical value obtained within the prior
month in order to ensure the adequacy of dialysis. If Kt/Vurea is not available, then
an average of the last 2 values of urea reduction ratio (URR) of at least 65%.

4. rhEPO use: Using the same rhEPO (epoetins or darbepoetin) with total weekly doses that
varied by no more than 50% during the prior 4 weeks (i.e., maximum vs. minimum total
weekly doses
5. Hgb concentrations 9.5-12.0 g/dL (inclusive).

6. Vitamin B12 above the lower limit of the reference range (may rescreen in two months).

7. Folate: >/= 2.0 ng/mL (may rescreen in one month).

8. Ferritin: >/=40 ng/mL with the absence of microcytic or hypochromic RBCs.

9. Transferrin saturation (TSAT): Within the reference range.

10. Iron replacement therapy: Stable maintenance dose of oral iron replacement therapy, if
required, that will be maintained throughout the study. NOTE: IV iron replacement
therapy is not allowed the two weeks prior to Screening through the end of the study
(Week 6).

11. QTc: QTcB <470 msec or QTcB <480 msec in subjects with bundle branch block obtained at
Screening Visit (based on Central Reader's interpretation).

12. Females: Eligible to participate if she is of childbearing potential, and must agree
to use one of the approved contraception methods from Screening until completion of
the Follow-up Visit OR of non-childbearing potential defined as pre-menopausal females
with a documented tubal ligation of hysterectomy; or postmenopausal defined as 12
months of spontaneous amenorrhea [in questionable cases a blood sample with
simultaneous follicle stimulating hormone (FSH)>40MIU/ml and estradiol <40pg/ml is
confirmatory]. Females on hormone replacement therapy (HRT) whose menopausal status is
in doubt will be required to use one of the approved contraception methods if they
wish to continue their HRT during the study. Otherwise they must discontinue HRT to
allow confirmation of post-menopausal status prior to study enrolment. For most forms
of HRT, at least 2 weeks will elapse between the cessation of therapy and the blood
draw; this interval depends on the type and dosage of HRT. Following confirmation of
their post-menopausal status, they can resume use of HRT during the study without use
of a contraceptive method.

13. Males: Must agree to use one of the approved contraceptive methods from the time of
Screening until completion of the Follow-up Visit.

Exclusion Criteria:

1. Dialysis modality: On peritoneal dialysis OR planned change in dialysis modality
within the study time period.

2. rhEPO Hyporesponders: As defined by an epoetin dose of >/=360 IU/kg/week IV or
darbepoetin dose of >/=1.8 µg/kg/week IV within the prior 8 weeks.

3. Renal transplant: Renal transplant anticipated or scheduled within the study time
period or subjects with a functioning renal transplant.

4. Mircera or Peginesatide: Current or prior use (within the prior 8 weeks) of Mircera
(methoxy polyethylene glycol epoetin beta) OR peginesatide.

5. Total CPK: >5x the upper limit of the reference range.

6. HIV: Positive HIV antibody.

7. History of myocardial infarction or acute coronary syndrome within the prior 6 months.

8. History of stroke or transient ischemic attacks (TIAs) within the prior 6 months.

9. Heart failure: Class III/IV heart failure, as defined by the New York Heart
Association (NYHA) functional classification system.

10. Hypertension: Poorly controlled hypertension, whether due to inadequate treatment, or
lack of treatment, is defined as follows:

- DBP >100 mmHg or SBP>160 mmHg for subjects taking hypertension medication(s)
before screening and dialysis, if required.

- DBP >105 mmHg or SBP>170 mmHg for subjects who are asked to hold hypertension
medication(s) before screening and dialysis.

11. Thrombotic Disease: History of thrombotic disease (e.g., venous thrombosis such as
deep vein thrombosis or pulmonary embolism, or arterial thrombosis such as new onset
or worsening limb ischemia requiring intervention), or other thrombosis related
condition except shunt thrombosis) within the prior 6 months.

12. Pulmonary hypertension: Known pulmonary hypertension and those at higher risk (than
normally associated with CKD) for pre-existing elevation in pulmonary pressure (e.g.,
significant heart failure or lung disease requiring supplemental oxygen, or those with
connective tissue diseases).

13. Inflammatory disease: Chronic inflammatory disease that could impact erythropoiesis
(e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac
disease).

14. Haematological disease: Any haematological disease including those affecting
platelets, the coagulation disorders (e.g., Protein C or S deficiency) or red blood
cells (e.g. sickle cell anemia, myelodysplastic syndromes, haematological malignancy,
myeloma, haemolytic anemia) or any other cause of anemia other than renal disease.

15. Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the
exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening
of abnormal liver function tests [alkaline phosphatase, alanine transaminase (ALT) or
aspartate transaminase (AST) > 2.0 x upper limit of normal (ULN) or total bilirubin >
1.5 x ULN]; or other hepatic abnormalities that in the opinion of the investigator
would preclude the subject from participation in the study.

16. Major surgery: (excluding vascular access surgery) Within the prior 12 weeks or
planned during the study.

17. Transfusion: Blood transfusion within the prior 12 weeks or an anticipated need for
blood transfusion during the study.

18. Ulcer and Active GI Bleeding: Evidence of active peptic, duodenal, or esophageal ulcer
disease OR GI bleeding within the prior 12 weeks.

19. Acute infection: Clinical evidence of acute infection or history of infection
requiring intravenous (IV) antibiotic therapy the eight weeks prior to Screening
through Day 1 (randomization).

20. Malignancy: History of malignancy within the prior 5 years or are receiving treatment
for cancer or those with a strong family history of cancer (e.g., familial cancer
disorders), with the exception of squamous cell or basal cell carcinoma of the skin
that has been definitively treated.

21. Eyes: History of proliferative retinopathy requiring treatment within the prior 12
months or macular edema requiring treatment.

22. Severe reactions: History of severe allergic or anaphylactic reactions or
hypersensitivity to excipients in the investigational product.

23. Drugs and supplements: Use of any prescription or non-prescription drugs or dietary
supplements that are prohibited from Screening until the Follow-up Visit.

24. Androgens: New androgen therapy or changes to pre-existing androgen regimen within the
prior 12 weeks.

25. Prior investigational product exposure: The Subject has participated in a clinical
trial and has received an experimental investigational product within the prior 30
days.

26. Protocol compliance: Unwillingness or inability to follow the procedures, or lifestyle
and/or dietary restrictions outlined in the protocol.

27. Other Conditions: Any condition which in the investigator's opinion should exclude the
subject from participating in the study.

28. Pregnancy or Lactation: Pregnant females as determined by positive serum hCG test OR
women who are lactating at Screening or during the trial.
We found this trial at
38
sites
Calgary, Alberta
?
mi
from
Calgary,
Click here to add this to my saved trials
Arlington, Texas 76014
?
mi
from
Arlington, TX
Click here to add this to my saved trials
Arvada, Colorado 80002
?
mi
from
Arvada, CO
Click here to add this to my saved trials
Asheville, North Carolina 28803
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Azusa, California 91702
?
mi
from
Azusa, CA
Click here to add this to my saved trials
Bakersfield, California 93309
?
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Bethesda, Maryland 20892
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
Brooklyn, New York 11215
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Charlotte, North Carolina 28203
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Coral Springs, Florida 33065
?
mi
from
Coral Springs, FL
Click here to add this to my saved trials
Denver, Colorado 80206
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Durham, North Carolina 27705
?
mi
from
Durham, NC
Click here to add this to my saved trials
Erie, Pennsylvania 16507
?
mi
from
Erie, PA
Click here to add this to my saved trials
Greenville, Texas 75402
?
mi
from
Greenville, TX
Click here to add this to my saved trials
Gurnee, Illinois 60031
?
mi
from
Gurnee, IL
Click here to add this to my saved trials
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Killeen, Texas 76543
?
mi
from
Killeen, TX
Click here to add this to my saved trials
Las Vegas, Nevada 89102
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Los Angeles, California 90025
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Lynwood, California 60262
?
mi
from
Lynwood, CA
Click here to add this to my saved trials
Macon, Georgia 31201
?
mi
from
Macon, GA
Click here to add this to my saved trials
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73112
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
Paragould, Arizona 72450
?
mi
from
Paragould, AZ
Click here to add this to my saved trials
Pembroke Pines, Florida 33028
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Pine Bluff, Arkansas 71603
?
mi
from
Pine Bluff, AR
Click here to add this to my saved trials
Riverside, California 92506
?
mi
from
Riverside, CA
Click here to add this to my saved trials
San Antonio, Texas 78258
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Southgate, Michigan 48195
?
mi
from
Southgate, MI
Click here to add this to my saved trials
Spring Hill, Florida 34608
?
mi
from
Spring Hill, FL
Click here to add this to my saved trials
Tempe, Arizona 85284
?
mi
from
Tempe, AZ
Click here to add this to my saved trials
Waterbury, Connecticut 06708
?
mi
from
Waterbury, CT
Click here to add this to my saved trials
West Hills, California 91307
?
mi
from
West Hills, CA
Click here to add this to my saved trials
Westminster, Colorado 80234
?
mi
from
Westminster, CO
Click here to add this to my saved trials
Whittier, California 90606
?
mi
from
Whittier, CA
Click here to add this to my saved trials
Winston-Salem, North Carolina 27103
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials